Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors
Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors
The present Competitive Intelligence Reportabout phosphodiesterease 4 (PDE-4) Inhibitors provides a competitor evaluation in the field of mainly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of June 2010. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects.
Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer’s disease are also studied clinically as indications for PDE-4 inhibitors.
The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Reportabout phosphodiesterease 4 (PDE-4) Inhibitors provides a competitor evaluation in the field of mainly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of June 2010. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects.
Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer’s disease are also studied clinically as indications for PDE-4 inhibitors.
The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
ORAL AND INHALED NON-SELECTIVE PDE-4 INHIBITORS
ORAL AND INHALED SELETIVE PDE-4 INHIBITORS
TOPICAL PDE-4 INHIBITORS
CORPORATE PDE-4 INHIBITOR R&D PIPELINES
ORAL AND INHALED SELETIVE PDE-4 INHIBITORS
TOPICAL PDE-4 INHIBITORS
CORPORATE PDE-4 INHIBITOR R&D PIPELINES
